International Stem Cell CORP (ISCO)
D
Pipeline Grade
Financial Position (from SEC Filings)
$0.9M
Cash & Equivalents
$0.1M
Quarterly Burn Rate
$1M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
No upcoming catalysts detected for this company.
Active Clinical Trials (3)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06620666 | NEUROmuscular Training for Enhanced AGE Longevity | OTHER | Active Not Recruiting | 390 |
| NCT05224960 | Human Umbilical Cord-derived Mesenchymal Stem Cells for Decompensated Cirrhosis (MSC-DLC-2) | PHASE2 | Recruiting | 140 |
| NCT05222555 | Safety and Pharmacokinetics Study of a Modified Tafasitamab IV Dosing Regimen Combined With Lenalidomide in R-R DLBCL Pa... | PHASE2 | Active Not Recruiting | 53 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.